Company Overview and News

0
MinRex Resources set to begin sampling program on its East Pilbara projects

2018-08-01 proactiveinvestors.com.au
MinRex Resources Ltd (ASX:MRR) is about to commence a further detailed geological evaluation and sampling program on the East Pilbara tenements that the company holds a 70% interest in.
MRR

0
MinRex Resources decides not to proceed with acquisition of Clean Power Resources

2018-06-22 proactiveinvestors.com.au
MinRex Resources Ltd (ASX:MRR) has completed due diligence of Clean Power Resources Pty Ltd, and has decided not to proceed with the acquisition.
MRR

0
MinRex Resources high-grade gold samples to map 2018 plan at East Pilbara

2018-06-22 proactiveinvestors.com.au
MinRex Resources Ltd (ASX: MRR) holds a portfolio of prospective projects in Australia, and the latest rock chip samples from the 70%-owned East Pilbara project have delivered high-grade gold.
MRR

0
MinRex Resources reveals maiden high-grade cobalt JORC resource

2018-06-06 proactiveinvestors.com.au
MinRex Resources Ltd (ASX:MRR) has completed a maiden JORC resource estimate for the Pacific Express Project on the north coast of New South Wales.
MRR

0
MinRex adds exposure to cobalt with acquisition

2018-03-26 australianmining.com.au
MinRex Resources has secured an agreement to acquire Clean Power Resources, the owner of three projects with cobalt and scandium potential in New South Wales and Western Australia.
MRR

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...